

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Stakeholders identified a number of potential equalities issues during consultation:
--

- | |
|--|
| <ul style="list-style-type: none">• One stakeholder noted obstructive hypertrophic cardiomyopathy (oHCM) is more prevalent in men than in women, although noting it is thought that the difference may be due to underdiagnosis in women.• One stakeholder noted women with oHCM have a poorer prognosis than men, including increased risk of HCM-related events including major adverse cardiovascular events and mortality, as well as higher healthcare resource use, including more hospitalisations with longer length of stay and more outpatient visits. The stakeholder also noted evidence from clinical trials suggests that aficamten has comparable efficacy in women and men• Multiple stakeholders noted that access to specialist treatment centres can be challenging for some people |
|--|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Gender is a protected characteristic under equalities legislation. The committee will consider the issues during development of the guidance. If
--

a positive recommendation is reached, the committee will need to consider any equality issues related to eligibility criteria in its decision-making. The committee will also consider any concerns relating to health inequalities.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name):Lorna Dunning

Date: 08/12/25